Last reviewed · How we verify
Arm A: Belantamab Mafodotin
Arm A: Belantamab Mafodotin is a Antibody-drug conjugate (ADC) Small molecule drug developed by PrECOG, LLC.. It is currently in Phase 3 development for Relapsed or refractory multiple myeloma. Also known as: GSK2857916, Blenrep, Belamaf.
Belantamab mafodotin is an antibody-drug conjugate that targets BCMA on multiple myeloma cells and delivers a cytotoxic payload to kill them.
Belantamab mafodotin is an antibody-drug conjugate that targets BCMA on multiple myeloma cells and delivers a cytotoxic payload to kill them. Used for Relapsed or refractory multiple myeloma.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Oncology Phase 3 boost
+3.0pp
Oncology Phase 3 trials have higher approval rates (~61%) than the cross-industry average due to clearer endpoints and FDA oncology pathway.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Arm A: Belantamab Mafodotin |
|---|---|
| Also known as | GSK2857916, Blenrep, Belamaf |
| Sponsor | PrECOG, LLC. |
| Drug class | Antibody-drug conjugate (ADC) |
| Target | BCMA (B-cell maturation antigen) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Belantamab mafodotin binds to B-cell maturation antigen (BCMA), a surface protein highly expressed on multiple myeloma cells. Upon binding, the drug is internalized and releases monomethyl auristatin F (MMAF), a microtubule-disrupting agent that induces apoptosis in myeloma cells. This targeted delivery mechanism allows concentration of cytotoxic activity at tumor cells while minimizing systemic toxicity.
Approved indications
- Relapsed or refractory multiple myeloma
Common side effects
- Corneal microdepots/keratopathy
- Thrombocytopenia
- Anemia
- Fatigue
- Nausea
Key clinical trials
- Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma (PHASE1, PHASE2)
- A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) (PHASE3)
- Selinexor and Backbone Treatments of Multiple Myeloma Patients (PHASE1, PHASE2)
- A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma (PHASE1)
- Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma (PHASE3)
- Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma (PHASE1, PHASE2)
- A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody (PHASE2)
- An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Arm A: Belantamab Mafodotin CI brief — competitive landscape report
- Arm A: Belantamab Mafodotin updates RSS · CI watch RSS
- PrECOG, LLC. portfolio CI
Frequently asked questions about Arm A: Belantamab Mafodotin
What is Arm A: Belantamab Mafodotin?
How does Arm A: Belantamab Mafodotin work?
What is Arm A: Belantamab Mafodotin used for?
Who makes Arm A: Belantamab Mafodotin?
Is Arm A: Belantamab Mafodotin also known as anything else?
What drug class is Arm A: Belantamab Mafodotin in?
What development phase is Arm A: Belantamab Mafodotin in?
What are the side effects of Arm A: Belantamab Mafodotin?
What does Arm A: Belantamab Mafodotin target?
Related
- Drug class: All Antibody-drug conjugate (ADC) drugs
- Target: All drugs targeting BCMA (B-cell maturation antigen)
- Manufacturer: PrECOG, LLC. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Relapsed or refractory multiple myeloma
- Also known as: GSK2857916, Blenrep, Belamaf
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing